Westlake Village biopharmaceutical company MannKind Corp. has entered a partnership with NRx pharmaceuticals to evaluate the feasibility of formulating a dry powder version of vasoactive intestinal peptide, or VIP, a substance produced by the human body that helps to protect cells against inflammatory conditions. ...

Subscribe to get the full story.


Are you a subscriber? Sign In